Leerink Swann analyst Howard Liang came out with some of his opinions on Celgene Corporation (NASDAQ:CELG) following the 13th International Conference on Malignant Lymphoma (ICML) …
Celgene Corporation (NASDAQ:CELG) announced that during its June meeting the Company’s Board of Directors authorized the repurchase of up to an additional $4.0 …
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) announced updated results of its pivotal phase III FIRSTTM (MM-020/IFM 07-01) trial, comparing …
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), announced that the findings from a long-term (104-week) post-hoc analysis of pooled data from …
Maxim Group analyst Jason McCarthy weighed in today with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the company made amendments on its …
In research report issued today, J.P.
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based …
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), announced that data from 11 abstracts (two oral presentations, six poster presentations and …
J.P.
Canaccord Genuity analyst John Newman was out pounding the table on Celgene Corporation (NASDAQ:CELG) Thursday, reiterating a Buy rating and price target of $156, which …
